- Home
- RGT vs SERA Comparison
RGT vs SERA Comparison
Compare RGT & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RGT | SERA |
|---|---|---|
| Founded | 1986 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Precision Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 95.0M | 77.2M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | RGT | SERA |
|---|---|---|
| Price | $13.71 | $2.13 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 21.4K | ★ 65.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 1.43% | N/A |
| EPS Growth | N/A | ★ 14.66 |
| EPS | ★ 0.92 | N/A |
| Revenue | N/A | ★ $77,000.00 |
| Revenue This Year | N/A | $25.84 |
| Revenue Next Year | N/A | $715.79 |
| P/E Ratio | $15.04 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.00 | $1.37 |
| 52 Week High | $14.99 | $4.20 |
Technical Indicators
Market Signals| Indicator | RGT | SERA |
|---|---|---|
| Relative Strength Index (RSI) | 39.25 | 41.29 |
| Support Level | $12.50 | $1.37 |
| Resistance Level | $14.95 | $3.45 |
| Average True Range (ATR) | 0.22 | 0.21 |
| MACD | -0.09 | 0.01 |
| Stochastic Oscillator | 14.31 | 44.09 |
Price Performance
Historical ComparisonAbout RGT Royce Global Value Trust Inc.
Royce Global Value Trust Inc is a diversified closed-end investment company. The fund spreads its investments across diversified sectors such as information technology, consumer discretionary, health care, materials, consumer staples, and energy. Geographically, it has presence in the region of the United Kingdom, Japan, the United States, Canada, France, Hong Kong, and Germany.
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.